Evolving therapeutic targets in renal cell carcinoma

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 273-280

  Singer, Eric A ^a   Gupta, Gopal N ^b   Marchalik, Daniel ^c   Srinivasan, Ramaprasad ^c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

clear cell; familial renal cancer; nonclear cell; renal cell carcinoma; targeted therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; FORETINIB; GLUCOSE TRANSPORTER 1; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TRANSFORMING GROWTH FACTOR ALPHA; TUBERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; HEREDITARY PAPILLARY RENAL CARCINOMA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MONOTHERAPY; OVERALL SURVIVAL; PAPILLARY RENAL CELL CARCINOMA; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR MICROENVIRONMENT;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876288112     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835fc857     Document Type: Review

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol 2012; 24:284-290.
3. Latif F, Tory K, Gnarra J, et al. Identification of the von hippel-lindau disease tumor suppressor gene. Science 1993; 260:1317-1320.
4. Linehan WM, Walther MM, Zbar B. The genetic basisofcancer of thekidney. J Urol 2003; 170 (6 Pt 1):2163-2172.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
7. Escudier B, Bellmunt J, Negrier S, et al. Phase iii trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (avoren): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
8. Rini BI, Halabi S, Rosenberg JE, et al. Phase iii trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of calgb 90206. J Clin Oncol 2010; 28:2137-2143.
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
10. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
12. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
13. Singer EA, Gupta GN, Srinivasan R. Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol 2011; 23:283-289.
14. Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012; 30:482-487.
15. Rini BI, Escudier BJ, Michaelson MD, et al. Phase iii axis trial for second-line metastatic renal cell carcinoma (mrcc): effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. J Clin Oncol 2012; 30 (5 Suppl):354.
16. Motzer R, Hutson TE, Reeves J, et al. Randomized, open-label, phase iii trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mrcc): results of the comparz trial. Ann Oncol 2012; 23 (Supplement 9):ixe13.
17. Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (paz) and sunitinib (sun): results of a randomized, double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (MRCC)-PISCES study, nct01064310. J Clin Oncol 2012; 30(18 Suppl).
18. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (av-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012; 30:1678-1685.
19. Motzer RJ, Nosov D, Elsen T, et al. Tivozanib versus sorafenib as intial targeted therapy for patients with advanced renal cell carcinoma: results from a phase iii randomized, open-label, multicenter trial. J Clin Oncol 2012; 30 (15 Suppl): 4501.
20. Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol 2009; 182:2132-2136.
21. Sukov WR, Lohse CM, Leibovich BC, et al. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol 2012; 187:54-59.
22. Keegan KA, Schupp CW, Chamie K, et al. Histopathology ofsurgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012; 188:391-397.
23. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10:537-544.
24. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 sub-classification. Urology 2007; 69:230-235.
25. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561-566.
26. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
27. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999; 155:517-526.
28. Cecchi F, Rabe DC, Bottaro DP. Targeting the hgf/met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:553-572.
29. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase ii and biomarker study of the dual met/vegfr2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181-186.
30. Delahunt B, Eble JN, Mccredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001; 32:590-595.
31. Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 2003; 170:764-767.
32. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in fh predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406-410.
33. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in north america. Am J Hum Genet 2003; 73:95-106.
34. Grubb RL 3rd, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007; 177:2074-2079; discussion 2079-2080.
35. Isaacs JS, Jung YJ, Mole DR, et al. Hif overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of hif stability. Cancer Cell 2005; 8:143-153.
36. Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers ampk levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011; 20:315-327.
37. Lu H, Dalgard CL, Mohyeldin A, et al. Reversible inactivation of hif-1 prolyl hydroxylases allows cell metabolism to control basal hif-1. J Biol Chem 2005; 280:41928-41939.
38. Ivan M, Kondo K, Yang H, et al. Hifalpha targeted for vhl-mediated destruction by proline hydroxylation: implications for o2 sensing. Science 2001; 292:464-468.
39. Yang Y, Valera V, Sourbier C, et al. A novel fumarate hydratase-deficient hlrcc kidney cancer cell line, uok268: a model of the warburg effect in cancer. Cancer Genet 2012; 205:377-390.
40. Yang Y, Valera VA, Padilla-Nash HM, et al. Uok 262 cell line, fumarate hydratase deficient (fh-/fh-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010; 196:45-55.
41. Singer EA, Marchalik D, Friend JC, et al. Efficacy of combined vegf and egfr inhibtion in metastatic papillary rencal cell carcinoma associated with hereditary leiomyomatosis and renal cell cancer. Can J Urol 2012; 19:6510.
42. Singer EA, Friend JC, Hawks G, et al. A phase ii study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer (RCC). J Clin Oncol 2012; 30 (Suppl):TS4680.
43. Cohen HT, Mcgovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490.
44. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23:2763-2771.
45. Tan MH, Wong CF, Tan HL, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 2010; 10:196.
46. Speicher MR, Schoell B, Du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994; 145:356-364.
47. Schmidt LS. Birt-hogg-dube syndrome, a genodermatosis that increases risk for renal carcinoma. Curr Mol Med 2004; 4:877-885.
48. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift bhd gene mutations in birt-hogg-dube-associated renal tumors. J Natl Cancer Inst 2005; 97:931-935.
49. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the birt-hogg-dube syndrome. Cancer Cell 2002; 2:157-164.
50. Baba M, Keller JR, Sun HW, et al. The folliculin-fnip1 pathway deleted in human birt-hogg-dube syndrome is required for murine b-cell development. Blood 2012; 120:1254-1261.
51. Baba M, Furihata M, Hong SB, et al. Kidney-targeted birt-hogg-dube gene inactivation in a mouse model: Erk1/2 and akt-mtor activation, cell hyperpro-liferation, and polycystic kidneys. J Natl Cancer Inst 2008; 100:140-154.
52. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
53. Larkin JM, Fisher RA, Pickering LM, et al. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol 2011; 29:e241-e242.
54. Paule B, Brion N. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. Anticancer Res 2011; 31:331-333.
55. Zardavas D, Meisel A, Samaras P, et al. Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Rep Oncol 2011; 4:16-18.
56. Shuch B, Vourganti S, Friend JC, et al. Targeting the mtor pathway in chromophobe kidney cancer. J Cancer 2012; 3:152-157.
57. Rosser T, Panigrahy A, Mcclintock W. The diverse clinical manifestations of tuberous sclerosis complex: a review. Semin Pediatr Neurol 2006; 13:27-36.
58. Leung AK, Robson WL. Tuberous sclerosis complex: a review. J Pediatr Healthcare 2007; 21:108-114.
59. Bjornsson J, Short MP, Kwiatkowski DJ, et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996; 149:1201-1208.
60. Habib SL, Yadav A, Mahimainathan L, et al. Regulation of pi 3-k, pten, p53, and mtor in malignant and benign tumors deficient in tuberin. Genes Cancer 2011; 2:1051-1060.
61. John J, Bissler JCK, Zonnenberg BA, et al. Everolimus therapy for angiomyo-lipoma in patients with tuberous sclerosis complex or sporadic lymphangio-leiomyomatosis: results from exist-2. J Clin Oncol 2012; 30(Suppl 5).
62. Bissler JJ, Mccormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-151.
63. Ricketts C, Woodward ER, Killick P, et al. Germline sdhb mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008; 100:1260-1262.
64. Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the warburg effect in cancer. J Urol 2012; 188:2063-2071.
65. Morris MR, Maina E, Morgan NV, et al. Molecular genetic analysis of fih-1, fh, and sdhb candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 2004; 57:706-711.
66. Schinstine M, Filie AC, Torres-Cabala C, et al. Fine-needle aspiration of a xp11.2 translocation/tfe3 fusion renal cell carcinoma metastatic to the lung: report of a case and review of the literature. Diagn Cytopathol 2006; 34:751-756.
67. Sidhar SK, Clark J, Gill S, et al. The t(x;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene prcc to the tfe3 transcription factor gene. Hum Mol Genet 1996; 5:1333-1338.
68. Zhong M, De Angelo P, Osborne L, et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol 2012; 36:654-662.
69. Bambury RBC, Mccarthy A, Fleming S, et al. Tanslocation renal cell carcinomas: an evolving entity. J Clin Oncol 2012; 30(Suppl 5).
70. Hua X, Liu X, Ansari DO, et al. Synergistic cooperation of tfe3 and smad proteins in tgf-beta-induced transcription of the plasminogen activator inhi-bitor-1 gene. Genes Dev 1998; 12:3084-3095.
71. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 2010; 34:1295-1303.
72. Tsuda M, Davis IJ, Argani P, et al. Tfe3 fusions activate met signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic met inhibition. Cancer Res 2007; 67:919-929.
73. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (arq 197), a selective inhibitor of met, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012; 118:5894-5902.
74. Figlin R, Sternberg C, Wood CG. Novel agents and approaches for advanced renal cell carcinoma. J Urol 2012; 188:707-715.